Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 18,953

Document Document Title
WO/2015/160793A1
Provided are novel biocompatible copolymers, compositions comprising the copolymers, and methods of using the copolymers. The copolymers are non-toxic and typically have an LCST below 37°C. Compositions comprising the copolymers can be ...  
WO/2015/158740A1
The present invention relates to compositions and methods for treating myotonic dystrophy.  
WO/2015/158836A1
The invention relates to a Mangifera (Mango) Indica preparation as Sirtuin 1 activating agent for in vivo and in vitro applications. The preparation may be used to reduce the risk of developping obesity, type II diabetes, elevated blood ...  
WO/2015/158365A1
The present invention relates to compositions and methods for treating myotonic dystrophy.  
WO/2015/161255A1
Disclosed herein are methods of treating and diagnosing muscular dystrophy. In some examples, the methods include treating muscular dystrophy by administering to the subject a therapeutically effective amount of an agent that alters the ...  
WO/2015/154721A1
An isoacteoside derivative and preparation method and use thereof; the isoacteoside derivative has a structure of formula (I): R1 and R2 are independently selected from hydrogen, halogen, hydroxyl and alkoxy oxyl; R3 and R4 are independe...  
WO/2015/156498A1
The present invention relates to a pharmaceutical composition containing an Oenothera odorata extract as an active ingredient for preventing or treating muscle atrophy, a method for preparing the same, and a food composition for preventi...  
WO/2015/150966A1
There is described a food supplement composition comprising a cucumber (Cucumis sativus) extract which in particular reduces the TNF-α level. Raw cucumber extract can inhibit the production of TNF-α in human blood without causing adver...  
WO/2015/154072A1
A topical treatment composition for treating muscle cramps, muscle stiffness, muscle pain or muscle spasms. The treatment composition includes a middle (mid) chain fatty acid (MCFA). A method of making the topical treatment composition i...  
WO/2015/150337A1
The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of ...  
WO/2015/150839A1
A compound of Formula I: R1 -L1 -C(A)(A') - CH2, - L2-R2 or a pharmaceutically acceptable salt thereof, for use in medicine, for example in the treatment of a disease or condition selected from the group comprising cancer, autistic spect...  
WO/2015/148982A1
Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increase...  
WO/2015/146929A1
Provided is a compound, or a salt thereof, that has an excellent PKC inhibitory action, and that is useful as a prophylactic or therapeutic agent for immunological diseases, inflammatory diseases, etc. A compound represented by formula (...  
WO/2015/149005A1
Methods and compositions for cell therapy using immune modulating peptides comprising a MANF family protein, or fragment thereof, as an adjuvant to improve replacement cell viability and integration. The methods and compositions can be u...  
WO/2015/135089A1
The invention relates to a method for treating a muscular dystrophy disease in a patient, said method including the administering of an effective quantity of a botanical medicine isolated from Andrographis paniculata, in combination with...  
WO/2015/137965A1
Liquids, substantially clear liquids and foodstuffs are described that contain free acid HMB. The liquids, substantially clear liquids and foodstuffs are substantially free of crude fat and may contain soluble proteins, carbohydrates, vi...  
WO/2015/137387A1
Provided are the following: a muscle enhancing drug containing, as an effective component, an amino acid composition consisting of ornithine or a salt thereof, citrulline or a salt thereof, and arginine or a salt thereof; and a compositi...  
WO/2015/137409A1
 Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 exon in the human dystrophin gene to be skipped.  
WO/2015/133627A1
 The present invention provides an agent to prevent or improve debility, the agent containing as an active ingredient isoleucine and threonine, and an agent to prevent or improve debility, the agent further containing as an active ingr...  
WO/2015/129821A1
The present invention provides a compound that has an autotaxin inhibitory effect and is represented by formula (I) (in the formula, R1, R2, R3, R4a, R4b, R5a, and R5b are as defined in the description.), a medicine that uses said compou...  
WO/2015/123750A1
Described is a transdermal ethosome composition for the treatment of pain. The transdermal ethosome composition comprises: an alcohol; a phospholipid; water; and a magnesium salt, a TRPV1 receptor agonist, or both a magnesium salt and a ...  
WO/2015/125138A1
The present invention relates to the alleviation of adverse side effects resulting from statin therapy. The present invention further relates to the use of an inhibitor of leukotriene C 4 (LTC4) mediated activity for alleviating at least...  
WO/2015/122067A1
Provided are: a citrus seed extract-containing composition with which a novel function of citrus (particularly, a citrus seed extract) can be sufficiently exhibited; a food; a drug; and a method for producing the citrus seed extract-cont...  
WO/2015/119126A1
The purpose of the present invention is to provide a novel compound having a selective JAK3-inhibiting effect and excellent oral absorption. Moreover, the purpose of the present invention is to provide a medical drug useful, on the basis...  
WO/2015/118019A1
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/119249A1
Provided are a novel myogenesis accelerator, amyotrophy suppressor, medicinal composition, and TAZ activator. The myogenesis accelerator, amyotrophy suppressor, medicinal composition, and TAZ activator according to the present invention ...  
WO/2015/118365A1
The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention r...  
WO/2015/118019A9
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/117010A3
Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, compr...  
WO/2015/111602A1
Provided are: a method for producing adult oligodendrocyte-type-2 astrocyte progenitor cells from proliferative oligodendrocyte-type-2 astrocyte progenitor cells; and a pharmaceutical composition having as an effectivecomponent thereof a...  
WO/2015/109935A1
The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholineste...  
WO/2015/109666A1
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...  
WO/2015/106268A1
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising a sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for ...  
WO/2015/106290A1
The present disclosure provides antibodies and antigen-binding fragments capable of penetrating cells via an ENT transporter, such as humanized antibodies. The disclosure also provides conjugates comprising the antibodies or antigen-bind...  
WO/2015/099175A1
The purpose of the present invention is to provide an antibody exhibiting antagonistic action against IL-33, in particular, an isolated human anti-IL-33 neutralizing monoclonal antibody or fragment thereof in which the amino acid sequenc...  
WO/2015/098963A1
Provided is a method for promoting the expression of calreticulin in at least one type of eukaryotic cell. Also provided is a synthetic peptide that can be used in said method. The method provided by the present invention includes prepar...  
WO/2015/093634A1
The present invention relates to a pharmaceutical composition containing an extract of Cichorium intybus as an active ingredient for preventing or treating myoatrophy; a food composition containing an extract of Cichorium intybus for pre...  
WO/2015/090232A1
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also pro...  
WO/2015/089575A1
The present invention relates generally to a method of diagnosing and/or monitoring the development or progress of chronic fatigue syndrome. More particularly, the present invention relates to a method of diagnosing and/or monitoring the...  
WO/2015/095713A1
The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using en...  
WO/2015/094772A1
Methods of increasing skeletal muscle protein synthesis in a subject are provided. Methods of increasing or maintaining mammalian target of rapamycin (mTOR) activation are also provided. Such methods include a step of administering at le...  
WO/2015/093901A1
The present invention relates to a composition containing TM-53 and TM-54 as an active ingredient for inducing or promoting myocyte differentiation, a pharmaceutical composition for muscle regeneration, and a pharmaceutical composition f...  
WO/2015/089452A1
The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free botulinum toxin composition exhibits a longer l...  
WO/2015/085118A1
The present invention is directed to a method of treating spasticity in a human subject, comprising administering intrathecally to the subject a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof...  
WO/2015/082938A1
The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof : (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substit...  
WO/2015/078935A1
The application relates to means, which derive from TAL effectors and TALENs. The structure of the means of the application is especially adapted for partial or full deletion of at least one DNA tandem repeat, more particularly for parti...  
WO/2015/077353A1
Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the...  
WO/2015/073813A3
Provided herein are interfering molecules and pharmaceutical combinations comprising such interfering molecules that modulate the Hippo signaling pathway. Also provided are methods of treating and preventing a disease or condition associ...  
WO/2015/069669A1
Nanostructure conjugates, methods for their preparation, and methods for their use are described. The nanostructure conjugates are useful in inhibiting, activating, and modulating extrasynaptic receptors and ion channels, and in treating...  
WO/2015/070158A1
The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduce...  

Matches 101 - 150 out of 18,953